CB4 Relief is formulated with VESIsorb®, a safe and effective water-soluble patented drug delivery pharmaceutical technology that can help dramatically improve the bioavailability of poorly absorbed ingredients such as CBD and terpenes, such as beta-caryophyllene.
A clinical trial with VESIsorb® products tested for improvement in CBD absorption showed a 4.4-fold increase in peak absorption (Cmax) and reached 3x faster plasma concentration (Tmax) than comparable CBD products without VESIsorb®1.
|CBD Performance Advantage (25 mg)||CB4 Relief||Normal CBD in MCT Oil||CB4 Advantage|
|CBD Cmax (Maximum concentration) -effect||13 ng/mL||3 ng/mL||4.4x more|
|CBD Tmax (Time to reach maximum concentration) -onset of action||1 hour||3 hours||3x faster|
There are peer-reviewed published clinical studies that show orally administered ingredients are absorbed faster and to a greater extent with VESIsorb® than products without.2
|BCP Performance Advantage (100 mg)||CB4 Relief||Normal CBD in MCT Oil||CB4 Advantage|
|BCP Cmax (Maximum concentration) -effect||205 ng/mL||58 ng/mL||3.6x more|
|BCP Tmax (Time to reach maximum concentration) -onset of action||1.4 hours||3.1 hours||2x faster|
1 Knaub K, et al. “A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects.” Molecules, vol.24, no.2964, Aug 2019
2 Modinger, Yvonne, et al. “Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS).” Molecules, vol.27(9), no.2860, May 2022